A GLP-1 dose keeps climbing, the scale has stopped, and the next appointment ends with the same sentence: let's go up a step. If that is where you are, we want to offer a different reading of the situation. A plateau is not automatically a dose problem. It is information about a system, and the system is bigger than the pen. Before the next titration, six things deserve to be measured, because in our experience most of what looks like drug failure is actually thyroid drift, muscle loss, an insulin resistance that was never treated, or a payment structure that profits every time the dose goes up.
That last one is not a metaphor. When the platform that prescribes your medication also marks it up, every dose increase is revenue. When the fee is flat, escalation has to earn its place with data.
- A stalled scale is a signal to measure, not automatically to escalate.
- Thyroid, insulin markers, lean mass, ferritin, sleep and adherence explain most GLP-1 plateaus that get blamed on the drug.
- Higher doses do produce more weight loss in trials, but they also produce more side effects and cost more every month.
- If nobody draws labs between titrations, the escalation is a guess wearing a prescription pad.
- Our fee is $299 a month at any dose, including none, so nothing we earn changes with your titration schedule.
What dose escalation actually buys
The trials are not shy about it: higher doses of these medications do produce more weight loss on average. In SURMOUNT-1, tirzepatide produced average reductions of roughly 15 to 20 percent of body weight over 72 weeks depending on dose, with individual results varying, and the higher dose arms outperformed the lower ones (the published trial is here). We are not going to pretend dose does not matter. It does.
But notice what the trials also show. The dose-response curve flattens. The gap between a mid dose and the top dose is smaller than the gap between nothing and a mid dose, and every step up the curve carries more nausea, more reflux, more fatigue, and in real-world pricing, a bigger monthly bill. The clinical question is never whether the top dose works. It is whether you are the person the top dose is for, which is a question about your body, not about the drug.
If you have been titrating for months and nobody has drawn a panel between dose changes, the escalations were not clinical decisions. They were schedule decisions. Ask for the labs before you accept the next one.
The six biomarkers we check before any titration
Thyroid. A thyroid that is technically in range but drifting can stall weight loss and mimic drug failure almost perfectly. We read the full panel, not just TSH, because the relationship between feeling wrong and testing normal is exactly the gap a thorough panel closes. If thyroid is the driver, the fix is thyroid medication, not a stronger GLP-1.
Fasting insulin and glucose markers. Insulin resistance is the upstream condition most of these patients are actually treating. If it is still unaddressed, a GLP-1 is doing half the job. Our guide to reversing insulin resistance with medical support covers what treating it looks like alongside the medication.
Signs of muscle loss. Muscle is the engine of glucose disposal and of resting metabolism. If the weight coming off is disproportionately muscle, the scale moves but the metabolism slows, and the plateau arrives on schedule. The panel plus a body-composition conversation tell us whether the next move is a dose or a protein target and a barbell.
Ferritin and B12. Iron and B12 deficiencies are quiet saboteurs of energy, and low energy quietly kills the training and daily movement that keep weight loss moving.
Lipids and inflammation. If ApoB and hs-CRP are improving, the medication is working on the cardiovascular axis even when the scale is stubborn. That changes what we would recommend.
The adherence and sleep history. Not a biomarker, but it travels with them. Missed doses, a stomach that never settled, untreated sleep apnea waking you six times a night: all three look like plateaus from the outside and none of them is fixed with a dose increase.
What this looks like inside the membership
We are a Cardiometabolic Optimization practice, and the membership is built around the panel this article keeps referencing. One flat fee covers a comprehensive Biomarker Audit every 90 days (ApoB, Lp(a), hs-CRP, HbA1c, lipids, insulin markers, and full hormone and thyroid panels) and the clinician relationship that reads it with you.
The fee is $299 a month. The first charge at sign-up is $598, which covers the first two months together: the intake, the first full panel, the clinical protocol and month two of care. If the clinician cannot accept you into care, the $598 hold is released and you are never charged; once accepted, the first two months are non-refundable. From month three it is $299 month to month, cancel any time.
Medication is a separate charge, billed directly by the pharmacy at the pharmacy's own price. We set nothing on it, see nothing on it and take nothing on it. That is the whole structural point: when the dose goes up, the pharmacy earns what it earns, and we earn the same $299 we earned the month before. We make money when you get healthier, not when your dose gets stronger. A patient whose dose is stable at the lowest effective strength is our favorite outcome, not our lost revenue.
The objection we hear most
"If I stop escalating, won't I just regain the weight?"
Sometimes, if the underlying drivers were never treated. That is exactly why the panel comes first. A patient whose plateau was thyroid gets treated for thyroid and keeps losing. A patient whose plateau was muscle gets protein and resistance training and stabilizes at a lower dose. A patient whose plateau is genuine pharmacology, and they exist, gets the dose increase, now justified by data rather than by reflex. What nobody gets is a permanent upward spiral of dose and price with nobody watching what changed.
Who this is not for
If you want a prescription pipeline that will titrate you to the maximum on a schedule with no labs in between, that exists, and it is often cheaper month one. We are built for the patient who wants to know why the plateau is happening before the bill goes up. If you need bariatric surgical evaluation or treatment outside our scope, we will say so during eligibility review rather than hold your fee.
FAQ
My GLP-1 dose keeps climbing but the weight has stalled. What should I ask for first?
Ask for labs before the next titration: a full thyroid panel, fasting insulin and glucose markers, and a conversation about muscle mass and protein intake. Thyroid drift, untreated insulin resistance and lean-mass loss explain most plateaus that get blamed on the drug.
Do higher GLP-1 doses really produce more weight loss?
On average, yes, though the curve flattens: in SURMOUNT-1 the top tirzepatide dose outperformed lower doses, but by margins that shrink as dose rises, with more side effects. Whether the top dose is right for you is a question about your labs and your body, not about the maximum number on the box.
Is it safe to hold at a lower GLP-1 dose?
Often yes, and it is a decision a clinician should make with your panel in front of them, not a decision you make alone. Holding at the lowest effective dose is a legitimate clinical outcome when the metabolic markers are improving.
Does GoodLife Health charge more when the dose goes up?
No. The $299 monthly fee is the same at every dose, including no prescription at all. Medication is billed separately by the pharmacy at its own price, and we take nothing from it.
What does the $598 first charge cover?
The first two months together in one charge: the clinical intake, the first comprehensive Biomarker Audit, the protocol, and month two of care. It is never charged if the clinician cannot accept you into care, and it is non-refundable once you are accepted. From month three it is $299 month to month, cancel any time.
Can you take over a GLP-1 I started elsewhere?
Usually yes, and the first thing we do is draw the panel that tells us whether your current dose is doing its job. You keep filling wherever the price is best; our fee covers the clinical layer, not the dispensing.
Related reading
- What happens after goal weight on a GLP-1
- How strength training changes GLP-1 weight loss results
- The best labs to request at a metabolic health checkup
- Medical weight loss at GoodLife Health
- Check your eligibility
References
- Jastreboff et al., Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), N Engl J Med 2022;387:205-216. 2022. pubmed.ncbi.nlm.nih.gov/35658024/